Clinical Trials Logo

Nasopharyngeal Carcinoma clinical trials

View clinical trials related to Nasopharyngeal Carcinoma.

Filter by:

NCT ID: NCT05431764 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Whole-target Consolidation Therapy Under Systemic Therapy for Oligometastatic Nasopharyngeal Carcinoma

Start date: June 20, 2022
Phase: Phase 2
Study type: Interventional

In this exploratory clinical trial, patients with newly diagnosed distant metastatic nasopharyngeal carcinoma were treated with gemcitabine+ cisplatin+PD-1 inhibitor regimen followed by whole-target radiotherapy (IMRT for local regional lesion, SBRT for distant metastasis) and PD-1 inhibitor long-term maintenance regimen. To investigate the efficacy and safety of "whole target" radiotherapy combined with immuno-maintenance therapy.

NCT ID: NCT05417139 Not yet recruiting - Clinical trials for Nasopharyngeal Carcinoma

Sintilimab Combined With Chemotherapy and Radiotherapy in Newly Diagnosed Metastatic Nasopharyngeal Carcinoma: A Multicenter Study

Start date: July 1, 2022
Phase: Phase 2
Study type: Interventional

To explore the progression-free survival rate (progression-free survival, PFS), overall survival (OS), objective response rate(objective response rate, ORR) and safety of patients with Sintilimab + GP chemotherapy combined with radiotherapy for newly diagnosed metastatic NPC.

NCT ID: NCT05415098 Not yet recruiting - Gastric Cancer Clinical Trials

Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas

Start date: September 30, 2022
Phase: Phase 1
Study type: Interventional

This is a multicenter, open-label, Phase 1 study that will be conducted in two parts. Part 1 is the dose escalation of APG-5918. Part 2 is the dose expansion of APG-5918. APG-5918 will be administered orally. It will be supplied in 50 mg and 200 mg tablets. Patients will be treated in 28-day cycles.

NCT ID: NCT05410743 Not yet recruiting - Clinical trials for Nasopharyngeal Carcinoma

177Lu-EB-LM3 in Nasopharyngeal Carcinoma

Start date: June 1, 2022
Phase: Phase 1
Study type: Interventional

This is an open-label, non-controlled, non-randomized study to investigate the long-lasting radiolabeled somatostatin analogue based peptide receptor radionuclide therapy and evaluate response to 177Lu-EB-LM3 in patients with advanced metastatic nasopharyngeal carcinoma. Different groups with doses of 1.11GBq(1.11GBq)(30 mCi) and 2.22GBq(2.22GBq) (60 mCi)of 177Lu-EB-LM3 will be injected intravenously. All patients will undergo 68Ga-DOTA-Octreotide(TATE) PET/CT scans before and after the treatment.

NCT ID: NCT05397769 Recruiting - Clinical trials for Induction Chemotherapy

Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial.

Start date: June 1, 2022
Phase: Phase 2
Study type: Interventional

Patients diagnosed with locally advanced nasopharyngeal carcinoma will be recruited in this study. All the patients will get 3 cycles of GP+ Envafolimab for the induction chemotherapy. After that, the patients will receive concurrent chemoradiotherapy. Radiotherapy will be given by IMRT, under the dose of GTVnx 68-70Gy/30-33f, 5d/w,6-7w, during which, every patient would receive 2 cycles of DDP+Envafolimab as concurrent chemotherapy. Then patients would receive Envafolimab every 3 weeks for maintenance treatment for a year, until disease progression or intolerance of treatment. . We aim to evaluate the three years progression free survival of these patients by the combination of Envafolimab with curative chemoradiotherapy.

NCT ID: NCT05389306 Not yet recruiting - Clinical trials for Nasopharyngeal Carcinoma

Combining MRI and CEUS to Diagnose Small Cervical Lymph Node Metastases in NPC Patients

NPC-LN
Start date: June 1, 2022
Phase: N/A
Study type: Interventional

This is a single-center diagnostic accuracy study, with the purpose to define the criteria to diagnose small cervical lymph node metastases in patients with nasopharyngeal carcinoma by combining MRI scanning and contrast-enhanced ultrasonography and evaluate the diagnostic performance of the criteria.

NCT ID: NCT05385926 Recruiting - Clinical trials for Metastatic Nasopharyngeal Cancer

Combining RT With Toripalimab and Chemotherapy in Metastatic Nasopharyngeal Carcinoma

Start date: May 5, 2022
Phase: Phase 2
Study type: Interventional

Incidences of de novo metastatic nasopharyngeal carcinoma range from 6% to 8% at the time of presentation. For the initial diagnosis of metastatic NPC, PD-1 plus chemotherapy yields a satisfactory outcome with1year PFS of 40%. Previous study demonstrated the benefit of adding radiotherapy to chemotherapy in metastatic NPC, however there is no evidence whether radiotherapy can further improve PFS based on chemotherapy plus PD-1 . The purpose of this study is to evaluate the safety and effectiveness of first-line immunochemotherapy combined with radiotherapy for initial diagnosed metastatic NPC.

NCT ID: NCT05352321 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Surgery Plus Target-reduction Chemoradiotherapy vs Regular Chemoradiotherapy for Primary Locally Resectable Nasopharyngeal Carcinoma

Start date: March 31, 2022
Phase: N/A
Study type: Interventional

Through a prospective clinical trial, we intend to combine endoscopic nasopharyngectomy, induction chemotherapy, target-reduction intensity-modulated radiotherapy and concurrent chemotherapy as an experimental treatment for patients with newly diagnosed resectable nasopharyngeal carcinoma to illuminate whether combined endoscopic nasopharyngectomy could bring patients better local control and lower adverse reactions.

NCT ID: NCT05350891 Recruiting - Clinical trials for Recurrent Nasopharyngeal Carcinoma

Transnasal Endoscopic Surgery Combined With Adjuvant Immunotherapy for Recurrent NPC

Start date: May 8, 2022
Phase: Phase 2
Study type: Interventional

A Prospective, Single-arm, Multicenter Clinical Study of Transnasal Endoscopic Surgery Combined With Adjuvant Immunotherapy for Recurrent Nasopharyngeal Carcinoma

NCT ID: NCT05342792 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma

Start date: April 17, 2022
Phase: Phase 3
Study type: Interventional

This trial is aimed to investigate whether additional adjuvant PD-1 antibody treatment could improve survival in high-risk nasopharyngeal carcinoma compared to metronomic capecitabine alone.